Unresectable Melanoma
Oncology
3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
3100%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Bristol Myers SquibbPRINCETON, NJ
2 programs1
1
NivolumabPhase 2Monoclonal Antibody1 trial
NivolumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bristol Myers SquibbNivolumab
Bristol Myers SquibbNivolumab
Clinical Trials (2)
Total enrollment: 155 patients across 2 trials
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Start: Aug 2013Est. completion: Feb 2021142 patients
Phase 2Completed
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Start: Oct 2021Est. completion: Feb 202513 patients
Phase 1/2Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
6h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
6h ago
Office Administrator
SystImmune
6h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
6h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
6h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
6h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space